Cargando…

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts

PURPOSE: The transforming growth factor-beta (TGF-β) signaling pathway is known to play a critical role in promoting tumor growth. Consequently, blocking this pathway has been found to inhibit tumor growth. In order to achieve an optimal anti-tumor effect, however, it remains to be established wheth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maier, Armin, Peille, Anne-Lise, Vuaroqueaux, Vincent, Lahn, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2015
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412926/ https://www.ncbi.nlm.nih.gov/pubmed/25573078 http://dx.doi.org/10.1007/s13402-014-0210-8

Ejemplares similares

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats
por: Liu, X., et al.
Publicado: (2016)

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
por: Kovacs, Richard J., et al.
Publicado: (2014)

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015)

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
por: Zhang, Qing, et al.
Publicado: (2018)

Therapeutic Effect of Polymeric Nanomicelles Formulation of LY2157299-Galunisertib on CCl(4)-Induced Liver Fibrosis in Rats
por: Panzarini, Elisa, et al.
Publicado: (2022)

Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
por: Dituri, Francesco, et al.
Publicado: (2013)

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2020)

Polymeric Nano-Micelles as Novel Cargo-Carriers for LY2157299 Liver Cancer Cells Delivery
por: Hanafy, Nemany Abdelhamid Nemany, et al.
Publicado: (2018)

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
Publicado: (2014)

Correction: Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II
por: Dituri, Francesco, et al.
Publicado: (2013)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
por: Giannelli, Gianluigi, et al.
Publicado: (2021)

Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts
por: Peterson, Joshua M., et al.
Publicado: (2022)

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine
por: Capper, David, et al.
Publicado: (2017)

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
por: Kelley, R.K., et al.
Publicado: (2019)

Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition
por: Schaer, David, et al.
Publicado: (2015)

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
por: Holmgaard, Rikke B., et al.
Publicado: (2018)

Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma
por: Peille, Anne-Lise, et al.
Publicado: (2020)

High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
por: Vuaroqueaux, Vincent, et al.
Publicado: (2023)

NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC
por: Cao, Yuan, et al.
Publicado: (2017)

Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib
Publicado: (2020)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2021)

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma
por: Harding, James J., et al.
Publicado: (2021)

Author Correction: Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma
por: Peille, Anne-Lise, et al.
Publicado: (2020)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer
por: Rodón, Jordi, et al.
Publicado: (2014)

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer
por: Gueorguieva, Ivelina, et al.
Publicado: (2016)

Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkers
por: Vuaroqueaux, Vincent, et al.
Publicado: (2021)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

LY6K depletion modulates TGF‐β and EGF signaling
por: Park, Sujeong, et al.
Publicado: (2023)

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro
por: Jank, Bernhard J., et al.
Publicado: (2022)

Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial
por: Chiorean, E. Gabriela, et al.
Publicado: (2023)

Mechanism of action and efficacy of LY2109761, a TGF-β receptor inhibitor, targeting tumor microenvironment in liver cancer after TACE
por: He, Xiaojun, et al.
Publicado: (2017)

Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes
por: Zhang, Chao, et al.
Publicado: (2016)

Galunisertib enhances chimeric antigen receptor-modified T cell function
por: Wang, Zhixiong, et al.
Publicado: (2020)

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
por: Nadal, Ernest, et al.
Publicado: (2023)

A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
por: Ikeda, Masafumi, et al.
Publicado: (2018)

TGF-β receptor inhibitor LY2109761 enhances the radiosensitivity of gastric cancer by inactivating the TGF-β/SMAD4 signaling pathway
por: Yang, Tian, et al.
Publicado: (2019)

Elevated MACC1 Expression in Colorectal Cancer Is Driven by Chromosomal Instability and Is Associated with Molecular Subtype and Worse Patient Survival
por: Vuaroqueaux, Vincent, et al.
Publicado: (2022)

Ly phenotype of cytotoxic T cells for syngeneic tumor
Publicado: (1976)

Cannot write session to /tmp/vufind_sessions/sess_1gnijfq8co8fmvlubctrgbllq4